Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor Dapagliflozin

Postgraduate Medicine

Volumn 124, Issue 4, 2012, Pages 62-73

  Jabbour, Serge A ^a   Whaley, Jean M ^b   Tirmenstein, Mark ^b   Poucher, Simon M ^c   Reilly, Timothy P ^b   Boulton, David W ^d   Saye, Joanne ^c   List, James F ^b   Parikh, Shamik ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Research and Development   (United States)

^c ASTRAZENECA   (United Kingdom)

^d Discovery Medicine and Clinical Pharmacology   (United States)

Author keywords

Dapaglifozin; Hyperglycemia; Kidney; SGLT2; Type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; DIGOXIN; EMPAGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PHLORIZIN; PIOGLITAZONE; PLACEBO; SIMVASTATIN; SITAGLIPTIN; VALSARTAN; VOGLIBOSE; WARFARIN; 2 (3 (4 ETHOXYBENZYL) 4 CHLOROPHENYL) 6 HYDROXYMETHYLTETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ARTICLE; BALANITIS; DRUG POTENCY; DRUG SELECTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE REABSORPTION; HUMAN; HYPOGLYCEMIA; INFECTION; KIDNEY TUBULE ABSORPTION; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; SIDE EFFECT; TOXIC HEPATITIS; URINARY TRACT INFECTION; VULVOVAGINITIS; WEIGHT GAIN; WEIGHT REDUCTION; DRUG ANTAGONISM; HOMEOSTASIS; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; REVIEW; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84871710497     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.07.2569     Document Type: Article

References (70)

1. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
2. Garber AJ. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Am J Manag Care. 2010;16(7 suppl):S187-S194.
3. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38(4):667-678.
4. Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care. 2009;32(suppl 2):S253-S259.
5. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
6. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
7. Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551-559.
8. Phillips PJ, Twigg SM. Oral hypoglycaemics-a review of the evidence. Aust Fam Physician. 2010;39(9):651-653.
9. Jorgensen CH, Gislason GH, Andersson C, et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention-a retrospective nationwide cohort study. Cardiovasc Diabetol. 2010;9:54.
10. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6): 539-545.
11. Rosenstock J, Arbit D, Usiskin K, Capuano G, Canovatchel W. Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes (T2D) on metformin [abstract]. Diabetes. 2010;59 (suppl 1):A21. Abstract 0077-OR.
12. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes and was well tolerated [abstract]. Diabetes. 2010;59 (suppl 1):A155. Abstract 0568-P.
13. National Institutes of Health. National diabetes statistics. National Diabetes Information Clearinghouse website. http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Accessed May 29, 2011.
14. Marsenic O Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53(5):875-883.
15. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008;14(6):782-790.
16. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733-794.
17. Guyton AC, Hall JE. Textbook of Medical Physiology. 11th ed. Philadelphia, PA: Elsevier Inc; 2006.
18. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008;62(8): 1279-1284.
19. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5(1):133-141.
20. Chen J, William S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010;1(2):57-92.
21. Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol. 1992;263(3 pt 2):F459-F465.
22. Freitas HS, Anhe GF, Melo KF, et al. Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology. 2008;149(2):717-724.
23. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427-3434.
24. White J. Apple trees to sodium glucose co-transproter inhibitors: a review of SGLT2 inhibition. Clin Diabetes. 2010;28(1):5-10.
25. Achard C, Delamare V The bark of the apple root, phlorizin, reduces diabetic hyperglycemia. Soc Medic Des Hopitaux. 1899:379-393.
26. Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999;48(9):1794-1800.
27. Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320(1):323-330.
28. Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol. 2009; 609(1-3):148-154.
29. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remoglifiozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008;327(1):268-276.
30. Jabbour SA. The importance of reducing hyperglycemia while preserving insulin secretion-the rationale for sodium-coupled glucose co-transporter 2 inhibition in diabetes. US Endocrinology. 2009;5(1):75-78.
31. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008; 51(5):1145-1149.
32. Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38(3):405-414.
33. Bellamine A, Smarsh M, Onorato J, et al. Dapagliflozin (BMS-512148) is a competitive, selective and reversible inhibitor of human SGLT2. Presented at: BioMedical Transporters; August 9, 2009; Thun, Switzerland.
34. Uveges A, Hagan D, Onorato J, et al. Dapagliflozin selectively inhibits human SGLT2 versus SGLT1, SMIT1, SGLT4, and SGLT6. Presented at: American Diabetes Association 71st Scientific Sessions; June 24-28, 2011; San Diego, CA. Poster P-987.
35. Poucher SM, De Schoolmeester J, Ehenborn J, Vernon W, Clementz T. Dapagliflozin selectivity for glucose transporters GLUT1, 2, and 4. Presented at: American Diabetes Association 71st Scientific Sessions; June 24-28, 2011; San Diego, CA. Poster P-1041.
36. Bristol Myers-Squibb, AstraZeneca. US Food and Drug Administration Endocrinologic and Metabolic Advisory Committee background document: dapagliflozin, BMS-512148, NDA 202293. US Food and Drug Administration. www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic-DrugsAdvisoryCommittee/ucm262993.htm. Accessed July 20, 2011.
37. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723-1729.
38. Zinker B, Ma X, Liu H, et al. Chronic dapagliflozin treatment reduces elevated hepatic glucose production and enhances pancreatic insulin content in male ZDF rats [abstract]. Diabetes. 2011;60(suppl 1):A283. Abstract 1031-P.
39. Macdonald FR, Peel JE, Jones HB, et al. The novel SGLT2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010;12(11): 1004-1012.
40. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes. 2011;60(3):890-898.
41. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650-657.
42. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85(5):513-519.
43. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care. 2010;33(10):2217-2224.
44. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-2233.
45. Bailey CJ, Gross JL, Yadav M, Iqbal N, Mansfield TA, List JF. Long-term efficacy of dapagliflozin as add-on to metformin (MET) in T2DM inadequately controlled with MET alone [abstract]. Diabetes. 2011;60(suppl 1):A271. Abstract 988-P.
46. Nauck MA, Del PS, Meier JJ, et al. Dapagliflozin versus glipizide as addon therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015-2022.
47. Nauck M, Del Prato S, Rohwedder K, Theuerkauf A, Langkilde A, Parikh S. Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results [abstract]. Presented at: American Diabetes Association 71st Scientific Sessions; June 24-28, 2011; San Diego, CA. Abstract 40-LB.
48. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446-456.
49. Rosenstock J, Vico M, Wei L, Salsali A, List J. Dapagliflozin added-on to pioglitazone reduces HbA1c and mitigates weight grain with low incidence of hypoglycemia in type 2 diabetes. [abstract]. Diabetes. 2011;60(suppl 1):A270. Abstract 986-P.
50. Strojek K, Yoon KH, Hruba B, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928-938.
51. Wilding JP, Woo V, Soler NG, et al; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405-415.
52. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes poorly controlled on insulin therapy- efficacy of a novel insulin-independent treatment [abstract]. Diabetes. 2010;59(suppl 1):A21-A22. Abstract 78-OR.
53. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Parikh S. Sustained effectiveness of dapagliflozin over 48 weeks in patients with type 2 dia betes poorly controlled with insulin [abstract]. Diabetes. 2010;59(suppl 1):LB7. Abstract 21-LB.
54. Yu PC, Bosnyak Z, Ceriello A. The importance of glycated haemoglobin (HbA1c) and postprandial glucose (PPG) control on cardiovascular outcomes in patients with type 2 diabetes. Diabetes Res Clin Pract. 2010;89(1):1-9.
55. Salsali A, Hruba V, Ying L, et al. Reduction in postprandial glucose with dapagliflozin in type 2 diabetes [abstract]. Diabetes. 2011;60(suppl 1):A286. Abstract 1104-P.
56. Salsali A, Bastien A, Mansfield T, Ying L, Ravichandran S, List J. Dapagliflozin improves hyperglycemia and beta-cell function without increasing hypoglycemic episodes in patients with type 2 diabetes mellitus. Presented at: American Association of Clinical Endocrinologists 19th Annual Meeting and Clinical Congress; April 21-25, 2010; Boston, MA.
57. Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel SGLT2 inhibitor, and metformin, pioglitazone, glimepiride, or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13(1):47-54.
58. Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29(2):163-177.
59. Wilcox CS, Liu X, Kasichayanula S, et al. Evaluation of interactions of dapagliflozin and bumetanide. Presented at: American Society of Nephrology; November 16-21, 2010; Denver, CO.
60. Rohwedder K, Hruba V, Salsali A, et al. Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has a low propensity to cause hypoglycemia in patients with type 2 diabetes [abstract]. Diabetes. 2011;60(suppl 1):A286. Abstract 1042-P.
61. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy [published online ahead of print March 23, 2010]. Diabetes Care.
62. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9): 1656-1662.
63. Parikh S, Johnsson K, Ptaszynska A, Schmitz B, Sugg J, List JF. Characterization of urinary tract infections in the setting of pharmacologically induced glucosuria [abstract]. Diabetes. 2011;60(suppl 1):A270. Abstract 984-P.
64. List JF, Ley S, Ptaszynska A, et al. Characterization of genital infections in the setting of pharmacologically-induced glucosuria [abstract]. Diabetes. 2011;60(suppl 1):A270. Abstract 985-P.
65. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103-1123.
66. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006;49(12):2819-2823.
67. Ptaszynska A, Johnsson K, Apanovitch AM, Sugg JE, Parikh SJ, List JF. Safety of dapagliflozin in clinical trials for T2DM. Presented at: American Diabetes Association; June 8-12, 2012; Philadelphia, PA.
68. Fioretto P, Solini A. Antihypertensive treatment and multifactorial approach for renal protection in diabetes. J Am Soc Nephrol. 2005;16(suppl 1):S18-S21.
69. Henry R, Murray A, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin-XR, or both together as initial therapy for T2DM [abstract]. Diabetes. 2011;60(suppl 1):A84. Abstract 307-OR.
70. Strojek K, Hruba V, Elze M, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus and inadequate glycaemic control on glimepiride monotherapy [abstract]. Diabetologia. 2010;53:S347. Abstract 870-P.